Evelo Biosciences Inc. (EVLO) Prices 12M Share Common Offering at $3.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
June 24, 2020 7:57 PM EDTCAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (Evelo), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, at a public offering price of $3.75 per share, before underwriting discounts and commissions. Evelo also granted the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional 1,800,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions... More
